Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19
Shots:
- The P-III ACTIV-3 trial plan to evaluate the safety & efficacy of Ensovibep (MP0420) vs PBO in 300 patients hospitalized with mild to moderate COVID-19. The first patient dosing is anticipated in Q2’21
- If the ensovibep treatment has a positive benefit/risk profile- the trial will enroll an additional 700 patients. Ensovibep is currently being evaluated in a P-I study and its data supports safety- tolerability and 2-3wks. the half-life of the therapy
- Additionally- the companies plan to initiate a global P- II/III EMPATHY study of Ensovibep in Q2’21. The study will enroll 2-000+ patients in the ambulatory setting
Ref: Molecular Partners | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com